{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transduced+Lymphocytes",
    "query": {
      "intervention": "Transduced Lymphocytes"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 63,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transduced+Lymphocytes&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T00:07:58.177Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03016377",
      "title": "Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Immune System Diseases",
        "Immunoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "iC9-CAR19 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "3 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-03-22",
      "completion_date": "2037-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016377"
    },
    {
      "nct_id": "NCT02070406",
      "title": "Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dendritic cell vaccine therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludeoxyglucose F 18",
          "type": "RADIATION"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2014-07-17",
      "completion_date": "2018-12-18",
      "has_results": false,
      "last_update_posted_date": "2019-02-28",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02070406"
    },
    {
      "nct_id": "NCT00871702",
      "title": "Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma, Non-Hodgkin",
        "Hodgkin Disease",
        "Myelodysplastic Syndromes",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "CD34-TK75 transduced donor lymphocytes",
          "type": "GENETIC"
        },
        {
          "name": "Sub Study - 18 FHBG PET/CT Scans",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "RADIATION"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-10",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2013-07-11",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00871702"
    },
    {
      "nct_id": "NCT02062359",
      "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2014-02",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2016-06-24",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02062359"
    },
    {
      "nct_id": "NCT00923390",
      "title": "Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cancer",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "2G-1 TCR Retroviral Vector-Transduced lyn",
          "type": "GENETIC"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 5,
      "start_date": "2009-03-02",
      "completion_date": "2012-08-24",
      "has_results": false,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923390"
    },
    {
      "nct_id": "NCT03354390",
      "title": "HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "cell infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 17,
      "start_date": "2018-07-20",
      "completion_date": "2029-03-03",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03354390"
    },
    {
      "nct_id": "NCT00003567",
      "title": "Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "1999-05",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003567"
    },
    {
      "nct_id": "NCT02051257",
      "title": "Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Transformed Recurrent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2014-06-19",
      "completion_date": "2027-03-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02051257"
    },
    {
      "nct_id": "NCT03745326",
      "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Colon Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "PET",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Chest x-ray",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Photography",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 5,
      "start_date": "2019-05-16",
      "completion_date": "2022-08-23",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03745326"
    },
    {
      "nct_id": "NCT00710892",
      "title": "CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Non-Hodgkin's Lymphoma",
        "Myelodysplastic Syndrome",
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Allodepleted T Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-12",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-09-09T00:07:58.177Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00710892"
    }
  ]
}